{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:33:25Z","timestamp":1784957605434,"version":"3.55.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sociedade Brasileira de Reumatologia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s42358-019-0056-x","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T14:24:26Z","timestamp":1556547866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases"],"prefix":"10.1186","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0054-7754","authenticated-orcid":false,"given":"Gecilmara Salviato","family":"Pileggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia Maria Henrique","family":"Da Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Maria","family":"Kakehasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Wagner","family":"De Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Karla Guedes","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Araujo M.","family":"da Fonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Bortoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claiton Viegas","family":"Brenol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Diniz Lopes","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrla","family":"Zaltman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Ferreira","family":"Borba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enio Ribeiro","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eutilia Andrade Medeiros","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro Mendes","family":"Klumb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges Basile","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieda Maria M.","family":"Laurindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Ballalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaias Pereira","family":"Da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lessandra","family":"Michelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian David","family":"de Azev\u00eado Valadares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana Andrade","family":"Chebli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Amazile Ferreira","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Alexandre","family":"Yazbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejane Maria R.","family":"De Abreu Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Kfouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Richtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma Da Costa Silva","family":"Merenlender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Valim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Renato","family":"De Assis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Candido","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia Fernandes Mo\u00e7a","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"56_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1473-3099(01)00016-0","volume":"1","author":"TP Monath","year":"2001","unstructured":"Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11\u201320.","journal-title":"Lancet Infect Dis"},{"issue":"RR-7","key":"56_CR2","first-page":"1","volume":"59","author":"JE Staples","year":"2010","unstructured":"Staples JE, Gershman M, Fischer M, Centers for Disease C, Prevention. Yellow fever vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2010;59(RR-7):1\u201327.","journal-title":"MMWR Recomm Rep"},{"key":"56_CR3","unstructured":"Brasil: Febre amarela - Guia para Profissionais de Sa\u00fade. Minist\u00e9rio da Sa\u00fade do Brasil.Bras\u00edlia; 2018."},{"key":"56_CR4","unstructured":"Febre amarela: Minist\u00e9rio da Sa\u00fade atualiza casos no pa\u00eds. In:[\n                    http:\/\/portalms.saude.boletim-epidemiologico\/noticias\/agencia-saude\/42940-febre-amarela-ministerio-da-saude-atualiza-casos-no-pais-6\n                    \n                  ]. Acess in 24\/nov\/2018."},{"issue":"1","key":"56_CR5","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4161\/hv.26549","volume":"10","author":"R Verma","year":"2014","unstructured":"Verma R, Khanna P, Chawla S. Yellow fever vaccine: an effective vaccine for travelers. Hum Vaccin Immunother. 2014;10(1):126\u20138.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"56_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","volume":"12","author":"AC Campi-Azevedo","year":"2016","unstructured":"Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016;12(2):491\u2013502.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"56_CR7","first-page":"11","volume":"25","author":"KR Cavalcante","year":"2016","unstructured":"Cavalcante KR, Tauil PL. Epidemiological characteristics of yellow fever in Brazil, 2000-2012. Epidemiol Serv Saude. 2016;25(1):11\u201320.","journal-title":"Epidemiol Serv Saude"},{"issue":"48","key":"56_CR8","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","volume":"26","author":"NP Lindsey","year":"2008","unstructured":"Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077\u201382.","journal-title":"Vaccine"},{"key":"56_CR9","volume-title":"Immunization Safety Surveillance: Guidelines for Immunization Programme Managers on Surveillance of Adverse Events Following Immunization Regional Office for the Western Pacific Region. World Health Organization","author":"WHO","year":"2013","unstructured":"WHO. Immunization Safety Surveillance: Guidelines for Immunization Programme Managers on Surveillance of Adverse Events Following Immunization Regional Office for the Western Pacific Region. World Health Organization. Manila: WHO Press; 2013."},{"issue":"14","key":"56_CR10","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","volume":"31","author":"JG Breugelmans","year":"2013","unstructured":"Breugelmans JG, Lewis RF, Agbenu E, Veit O, Jackson D, Domingo C, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013;31(14):1819\u201329.","journal-title":"Vaccine"},{"issue":"43","key":"56_CR11","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","volume":"27","author":"A Whittembury","year":"2009","unstructured":"Whittembury A, Ramirez G, Hernandez H, Ropero AM, Waterman S, Ticona M, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009;27(43):5974\u201381.","journal-title":"Vaccine"},{"issue":"1","key":"56_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/14760584.2018.1406800","volume":"17","author":"CC Ferreira","year":"2018","unstructured":"Ferreira CC, Campi-Azevedo AC, Peruhype-Magalhaes V, Costa-Pereira C, Albuquerque CP, Muniz LF, Yokoy de Souza T, et al. The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences. Expert Rev Vaccines. 2018;17(1):79\u201390.","journal-title":"Expert Rev Vaccines"},{"key":"56_CR13","doi-asserted-by":"crossref","unstructured":"Chiodini J. The CDC yellow book app 2018. Travel Med Infect Dis. 2017.","DOI":"10.1016\/j.tmaid.2017.10.014"},{"issue":"33","key":"56_CR14","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","volume":"30","author":"MD Gershman","year":"2012","unstructured":"Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Camacho LA, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30(33):5038\u201358.","journal-title":"Vaccine"},{"key":"56_CR15","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.2147\/DDDT.S99600","volume":"10","author":"RE Thomas","year":"2016","unstructured":"Thomas RE. Yellow fever vaccine-associated viscerotropic disease: current perspectives. Drug Des Devel Ther. 2016;10:3345\u201353.","journal-title":"Drug Des Devel Ther"},{"key":"56_CR16","volume-title":"Vaccine","author":"JE Staples","year":"2017","unstructured":"Staples JE, Gershman MD. Yellow fever vaccines. In: Plotkin SAOW, Offit PA, Edwards KM, editors. Vaccine. 7th ed. Philadelhia: Elsevier; 2017.","edition":"7"},{"issue":"49","key":"56_CR17","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1016\/j.vaccine.2014.05.003","volume":"32","author":"R Martins","year":"2014","unstructured":"Martins R, Pavao AL, de Oliveira PM, dos Santos PR, Carvalho SM, Mohrdieck RF, et al. Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil. Vaccine. 2014;32(49):6676\u201382.","journal-title":"Vaccine"},{"issue":"3","key":"56_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","volume":"89","author":"E Gotuzzo","year":"2013","unstructured":"Gotuzzo E, Yactayo S, Cordova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89(3):434\u201344.","journal-title":"Am J Trop Med Hyg"},{"issue":"23","key":"56_CR19","first-page":"647","volume":"64","author":"JE Staples","year":"2015","unstructured":"Staples JE, Bocchini JA, Rubin L Jr, Fischer M. Yellow fever vaccine booster doses: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(23):647\u201350.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"56_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","volume":"15","author":"IJ Amanna","year":"2016","unstructured":"Amanna IJ, Slifka MK. Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Rev Vaccines. 2016;15(12):1519\u201333.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"56_CR21","doi-asserted-by":"publisher","first-page":"e0149871","DOI":"10.1371\/journal.pone.0149871","volume":"11","author":"RW Wieten","year":"2016","unstructured":"Wieten RW, Jonker EF, van Leeuwen EM, Remmerswaal EB, Ten Berge IJ, de Visser AW, et al. A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PLoS One. 2016;11(3):e0149871.","journal-title":"PLoS One"},{"key":"56_CR22","unstructured":"Ahuka-Mundeke S, Casey RM, Harris JB, Dixon MG, Nsele PM, Kizito GM, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - preliminary report. N Engl J Med. 2018."},{"issue":"4","key":"56_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/v9040077","volume":"9","author":"Alan Watson","year":"2017","unstructured":"Watson AM, Klimstra WB. T cell-mediated immunity towards yellow fever virus and useful animal models. Viruses. 2017;9(4).","journal-title":"Viruses"},{"issue":"6","key":"56_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","volume":"40","author":"M Simoes","year":"2012","unstructured":"Simoes M, Camacho LA, Yamamura AM, Miranda EH, Cajaraville AC, da Silva Freire M. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals. 2012;40(6):399\u2013404.","journal-title":"Biologicals"},{"issue":"5","key":"56_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177882","volume":"12","author":"S Mercier-Delarue","year":"2017","unstructured":"Mercier-Delarue S, Durier C, Colin de Verdiere N, Poveda JD, Meiffredy V, Fernandez Garcia MD, et al. Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype. PLoS One. 2017;12(5):e0177882.","journal-title":"PLoS One"},{"issue":"3","key":"56_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.vaccine.2010.08.046","volume":"29","author":"ML Silva","year":"2011","unstructured":"Silva ML, Martins MA, Espirito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JG, et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine. 2011;29(3):583\u201392.","journal-title":"Vaccine"},{"issue":"282","key":"56_CR27","doi-asserted-by":"publisher","first-page":"282ra248","DOI":"10.1126\/scitranslmed.aaa3700","volume":"7","author":"SA Fuertes Marraco","year":"2015","unstructured":"Fuertes Marraco SA, Soneson C, Cagnon L, Gannon PO, Allard M, Abed Maillard S, et al. Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile upon yellow fever vaccination. Sci Transl Med. 2015;7(282):282ra248.","journal-title":"Sci Transl Med"},{"issue":"4","key":"56_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1586\/eci.13.10","volume":"9","author":"J Bayry","year":"2013","unstructured":"Bayry J, Radstake TR. Immune-mediated inflammatory diseases: progress in molecular pathogenesis and therapeutic strategies. Expert Rev Clin Immunol. 2013;9(4):297\u20139.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"56_CR29","doi-asserted-by":"publisher","first-page":"J163","DOI":"10.1016\/j.jaut.2009.12.005","volume":"34","author":"P Youinou","year":"2010","unstructured":"Youinou P, Pers JO, Gershwin ME, Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmun. 2010;34(3):J163\u20137.","journal-title":"J Autoimmun"},{"key":"56_CR30","first-page":"w14159","volume":"145","author":"S Buhler","year":"2015","unstructured":"Buhler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015;145:w14159.","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"56_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ard.2010.137216","volume":"70","author":"S Assen van","year":"2011","unstructured":"van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"56_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00296-013-2907-9","volume":"34","author":"D Papadopoulou","year":"2014","unstructured":"Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int. 2014;34(2):151\u201363.","journal-title":"Rheumatol Int"},{"issue":"9","key":"56_CR33","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.vaccine.2017.01.048","volume":"35","author":"E Croce","year":"2017","unstructured":"Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Buhler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - a systematic review of randomized trials, observational studies and case reports. Vaccine. 2017;35(9):1216\u201326.","journal-title":"Vaccine"},{"issue":"4","key":"56_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/erv.12.6","volume":"11","author":"TP Monath","year":"2012","unstructured":"Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012;11(4):427\u201348.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"56_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1590\/S0037-86822009000100006","volume":"42","author":"LM Mota","year":"2009","unstructured":"Mota LM, Oliveira AC, Lima RA, Santos-Neto LL, Tauil PL. Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop. 2009;42(1):23\u20137.","journal-title":"Rev Soc Bras Med Trop"},{"key":"56_CR36","volume-title":"Cochrane handbook for systematic reviews of interventions, vol. Version 5.1.0: Cochrane Colaborations","author":"JPTGS Higgins","year":"2011","unstructured":"Higgins JPTGS. Cochrane handbook for systematic reviews of interventions, vol. Version 5.1.0: Cochrane Colaborations; 2011."},{"key":"56_CR37","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [\n                    http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\n                    \n                  ]. Accessed Dec 2018."},{"issue":"7650","key":"56_CR38","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"56_CR39","unstructured":"Howick J. CI, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, Moschetti I, OCEBM Levels of Evidence Working Group et al. \u201cThe Oxford Levels of Evidence 2\u201d. . In.: Oxford Centre for Evidence-Based Medicine; 2011."},{"issue":"3","key":"56_CR40","first-page":"655","volume":"38","author":"SS McMillan","year":"2016","unstructured":"McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38(3):655\u201362.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"56_CR41","first-page":"713","volume":"72","author":"RW Wieten","year":"2016","unstructured":"Wieten RW, Goorhuis A, Jonker EFF, de Bree GJ, de Visser AW, van Genderen PJJ, et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J Inf Secur. 2016;72(6):713\u201322.","journal-title":"J Inf Secur"},{"issue":"10","key":"56_CR42","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.vaccine.2016.01.037","volume":"34","author":"RW Wieten","year":"2016","unstructured":"Wieten RW, Jonker EF, Pieren DK, Hodiamont CJ, van Thiel PP, van Gorp EC, et al. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication. Vaccine. 2016;34(10):1247\u201351.","journal-title":"Vaccine"},{"key":"56_CR43","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.1016\/j.rbr.2017.07.537","volume":"57","author":"C.C. Ferreira","year":"2017","unstructured":"Ferreira CC, Campi-Azevedo ACV, Peruhype-Magalh\u00e3es V, Freire LC, Albuquerque CP, Muniza LF, et al. Imunidade vacinal antiamar\u00edlica em pacientes com artrite reumatoide. Rev BrasReum. 57:381.","journal-title":"Revista Brasileira de Reumatologia"},{"issue":"6","key":"56_CR44","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/acr.20045","volume":"62","author":"M Scheinberg","year":"2010","unstructured":"Scheinberg M, Guedes-Barbosa LS, Mangueira C, Rosseto EA, Mota L. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken). 2010;62(6):896\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"56_CR45","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.38960","volume":"67","author":"AC Oliveira","year":"2015","unstructured":"Oliveira AC, Mota LM, Santos-Neto LL, Simoes M, Martins-Filho OA, Tauil PL. Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever. Arthritis Rheumatol. 2015;67(2):582\u20133.","journal-title":"Arthritis Rheumatol"},{"key":"56_CR46","doi-asserted-by":"publisher","first-page":"S 52","DOI":"10.1016\/j.rbr.2017.06.092","volume":"57","author":"V Valim","year":"2017","unstructured":"Valim V, Gouveia SA, de Lima SMB, Azevedo ACC, Carvalho AT, Pascoal VPM, et al. Efic\u00e1cia e seguran\u00e7a da vacina\u00e7\u00e3o anti-amar\u00edlica a curto e longo prazo em pacientes com doen\u00e7as reum\u00e1ticas imunomediadas em tratamento. Rev Bras Reumatol. 2017;57:S 52\u20133.","journal-title":"Rev Bras Reumatol"},{"key":"56_CR47","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.rbr.2017.06.119","volume":"57","author":"KLL Lira","year":"2017","unstructured":"Lira KLL, Balarini L, de Lima SMB, Azevedo ACC, de Carvalho AT, Paschoal VPM, et al. Vacina\u00e7\u00e3o anti-amar\u00edlica em pacientes com doen\u00e7as reum\u00e1ticas imunomediadas: an\u00e1lise retrospectiva. Rev Bras Reumat. 2017;57:S69.","journal-title":"Rev Bras Reumat"},{"issue":"9","key":"56_CR48","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/acr.22021","volume":"65","author":"S Kerneis","year":"2013","unstructured":"Kerneis S, Launay O, Ancelle T, Iordache L, Naneix-Laroche V, Mechai F, et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study. Arthritis Care Res (Hoboken). 2013;65(9):1522\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"56_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jtm.12209","volume":"22","author":"ER Nash","year":"2015","unstructured":"Nash ER, Brand M, Chalkias S. Yellow fever vaccination of a primary Vaccinee during adalimumab therapy. J Travel Med. 2015;22(4):279\u201381.","journal-title":"J Travel Med"},{"issue":"5","key":"56_CR50","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0277-9536(96)00221-3","volume":"44","author":"C Charles","year":"1997","unstructured":"Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44(5):681\u201392.","journal-title":"Soc Sci Med"},{"issue":"9","key":"56_CR51","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1080\/21645515.2015.1022700","volume":"11","author":"R Menezes Martins de","year":"2015","unstructured":"de Menezes Martins R, Fernandes Leal Mda L, Homma A. Serious adverse events associated with yellow fever vaccine. Hum Vaccin Immunother. 2015;11(9):2183\u20137.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"56_CR52","doi-asserted-by":"publisher","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","volume":"23","author":"Nicole P. Lindsey","year":"2016","unstructured":"Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE. Adverse event reports following yellow fever vaccination, 2007-13. J Travel Med. 2016;23(5).","journal-title":"Journal of Travel Medicine"},{"issue":"24","key":"56_CR53","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/j.vaccine.2013.04.009","volume":"31","author":"MM McNeil","year":"2013","unstructured":"McNeil MM, Li R, Pickering S, Real TM, Smith PJ, Pemberton MR. Who is unlikely to report adverse events after vaccinations to the vaccine adverse event reporting system (VAERS)? Vaccine. 2013;31(24):2673\u20139.","journal-title":"Vaccine"},{"issue":"5","key":"56_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1586\/14760584.2015.1029460","volume":"14","author":"S Tafuri","year":"2015","unstructured":"Tafuri S, Gallone MS, Calabrese G, Germinario C. Adverse events following immunization: is this time for the use of WHO causality assessment? Expert Rev Vaccines. 2015;14(5):625\u20137.","journal-title":"Expert Rev Vaccines"},{"issue":"44","key":"56_CR55","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1016\/j.vaccine.2013.08.087","volume":"31","author":"AE Tozzi","year":"2013","unstructured":"Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013;31(44):5041\u20136.","journal-title":"Vaccine"},{"issue":"11","key":"56_CR56","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.vaccine.2014.01.015","volume":"32","author":"C Biscayart","year":"2014","unstructured":"Biscayart C, Carrega ME, Sagradini S, Gentile A, Stecher D, Orduna T, et al. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina. Vaccine. 2014;32(11):1266\u201372.","journal-title":"Vaccine"},{"issue":"11","key":"56_CR57","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","volume":"12","author":"P Cottin","year":"2013","unstructured":"Cottin P, Niedrig M, Domingo C. Safety profile of the yellow fever vaccine Stamaril(R): a 17-year review. Expert Rev Vaccines. 2013;12(11):1351\u201368.","journal-title":"Expert Rev Vaccines"},{"issue":"25","key":"56_CR58","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","volume":"23","author":"AY Khromava","year":"2005","unstructured":"Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine. 2005;23(25):3256\u201363.","journal-title":"Vaccine"},{"issue":"17\u201318","key":"56_CR59","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.vaccine.2004.01.026","volume":"22","author":"S Kitchener","year":"2004","unstructured":"Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine. 2004;22(17\u201318):2103\u20135.","journal-title":"Vaccine"},{"issue":"49","key":"56_CR60","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1016\/j.vaccine.2013.09.030","volume":"31","author":"E Rafferty","year":"2013","unstructured":"Rafferty E, Duclos P, Yactayo S, Schuster M. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review. Vaccine. 2013;31(49):5798\u2013805.","journal-title":"Vaccine"},{"issue":"2","key":"56_CR61","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","volume":"86","author":"RE Thomas","year":"2012","unstructured":"Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg. 2012;86(2):359\u201372.","journal-title":"Am J Trop Med Hyg"},{"issue":"28","key":"56_CR62","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","volume":"29","author":"RE Thomas","year":"2011","unstructured":"Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine. 2011;29(28):4544\u201355.","journal-title":"Vaccine"},{"issue":"2","key":"56_CR63","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2016.02.1240","volume":"76","author":"A Caplan","year":"2017","unstructured":"Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: Infectious complications and vaccination recommendations. J Am Acad Dermatol. 2017;76(2):191\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"56_CR64","doi-asserted-by":"publisher","unstructured":"Ekenberg C, Friis-Moller N, Ulstrup T, Aalykke C. Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate. BMJ Case Rep. 2016;2016. \n                    https:\/\/doi.org\/10.1136\/bcr-2016-215403\n                    \n                  .","DOI":"10.1136\/bcr-2016-215403"},{"key":"56_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2017.03.011","volume":"80","author":"A Lopez","year":"2017","unstructured":"Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10\u201327.","journal-title":"J Autoimmun"},{"issue":"9","key":"56_CR66","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1055\/s-0042-109871","volume":"54","author":"J Ruddel","year":"2016","unstructured":"Ruddel J, Schleenvoigt BT, Schuler E, Schmidt C, Pletz MW, Stallmach A. Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: a case report. Z Gastroenterol. 2016;54(9):1081\u20134.","journal-title":"Z Gastroenterol"},{"key":"56_CR67","doi-asserted-by":"crossref","unstructured":"Tarazona B, Diaz-Menendez M, Mato Chain G. International travelers receiving pharmacological immunosuppression: challenges and opportunities. Med Clin (Barc). 2017.","DOI":"10.1016\/j.medcle.2018.01.011"},{"issue":"1","key":"56_CR68","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1590\/S0482-50042013000100001","volume":"53","author":"CV Brenol","year":"2013","unstructured":"Brenol CV, da Mota LM, Cruz BA, Pileggi GS, Pereira IA, Rezende LS, et al. 2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis. Rev Bras Reumatol. 2013;53(1):4\u201323.","journal-title":"Rev Bras Reumatol"},{"issue":"RR-17","key":"56_CR69","first-page":"1","volume":"51","author":"MS Cetron","year":"2002","unstructured":"Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, et al. Yellow fever vaccine. Recommendations of the advisory committee on immunization practices (ACIP), 2002. MMWR Recomm Rep. 2002;51(RR-17):1\u201311 quiz CE11-14.","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"56_CR70","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309\u201318.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"56_CR71","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1128\/JCM.01775-10","volume":"49","author":"C Domingo","year":"2011","unstructured":"Domingo C, Yactayo S, Agbenu E, Demanou M, Schulz AR, Daskalow K, Niedrig M. Detection of yellow fever 17D genome in urine. J Clin Microbiol. 2011;49(2):760\u20132.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"56_CR72","first-page":"34","volume":"59","author":"CDC","year":"2009","unstructured":"CDC. Transfusion-related transmission of yellow fever vaccine virus--California. MMWR Morb Mortal Wkly Rep 2010. 2009;59(2):34\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep 2010"},{"issue":"5","key":"56_CR73","first-page":"130","volume":"59","author":"CDC","year":"2009","unstructured":"CDC. Transmission of yellow fever vaccine virus through breast-feeding - Brazil. MMWR Morb Mortal Wkly Rep 2010. 2009;59(5):130\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep 2010"},{"issue":"4","key":"56_CR74","doi-asserted-by":"publisher","first-page":"E243","DOI":"10.1503\/cmaj.100619","volume":"183","author":"S Kuhn","year":"2011","unstructured":"Kuhn S, Twele-Montecinos L, MacDonald J, Webster P, Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ. 2011;183(4):E243\u20135.","journal-title":"CMAJ"},{"issue":"10","key":"56_CR75","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.pec.2015.06.022","volume":"98","author":"AM Stiggelbout","year":"2015","unstructured":"Stiggelbout AM, Pieterse AH, De Haes JC. Shared decision making: concepts, evidence, and practice. Patient Educ Couns. 2015;98(10):1172\u20139.","journal-title":"Patient Educ Couns"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-019-0056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-019-0056-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-019-0056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T23:17:40Z","timestamp":1588029460000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-019-0056-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1186\/s42358-019-0056-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"17 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Approved by all authors, the corresponding author assumes responsibility.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Adriana Maria Kakehasi Research funds: CNPq, SBR, FAPEMIG Support for Scientific Events: Abbvie, BMS, Janssen Lecture Fees: UCB, Janssen, Pfizer, Roche, BMS Clinical research: Roche, Pfizer Advisory board: Janssen, Roche, BMS, Pfizer.Alexandre Wagner S de Souza has received financial support as an advisory board member for Roche. Financial competing interest: none.Caroline Ara\u00fajo Magnata da Fonte: none.Clayton Brenol Has received personal or institutional support from Abbvie, Bristol, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by Abbvie, Pfizer and Roche. Financial competing interest: none.Claudia Marques: Non-financial and financial competing interests related to this publicationCyrla Zaltman: Non-financial and financial competing interests related to this publicationEduardo Ferreira Borba was supported by grants from Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq #307226\/2014-0). Financial competing interest: none.Gecilmara Salviato Pileggi has received fees for lectures and talks at events related to this study sponsored by Abbvie, Janssen, and UCB. The authors declare no financial competing interest.Georges Basile Christopoulos: noneIeda M M Laurindo \u2013 has no competing interests related to this work. Financial competing interests: none.Isabella Ballalai: has received funding for meetings related to this work sponsored by the Brazilian Ministry of Health (CTAI-PNI), fees for lectures and advisory board sponsored by Sanofi Pasteur, Pfizer and MSD.Izaias Pereira da Costa Non-financial competing interestsLessandra Michelin has received funding for meetings related to this work sponsored by the Brazilian Ministry of Health (CTAI-PNI). Financial competing interest: none.Licia Maria Henrique da Mota Has received personal or institutional support from Abbvie, Janssen, Pfizer and Roche; has delivered speeches at events related to this work and sponsored by Abbvie, Janssen, Pfizer, Roche and UCB. Financial competing interest: none.Lilian David de Azev\u00eado Valadares has received for lectures fees and speeches at events related to this work sponsored by Janssen and Novartis. Financial competing interest: none.Liliana Andrade Chebli has received for lecture fees and speeches at events not related to this work sponsored by Takeda. Financial competing interest: none.Marcos Renato de Assis has received personal or institutional support from Apsen and Lilly; has given lectures and\/or consultancy to Novartis, UCB and Janssen not related to this work. Financial competing interest: none.Marcus Vin\u00edcius Guimar\u00e3es de Lacerda has no conflict of interest.Michel Alexandre Yazbek has no competing interests related to this work. Financial competing interests: none.Rejane Maria Rodrigues de Abreu Vieira has no conflicts of interest.Renato Kfouri has received fees for lectures and advisory board sponsored by Sanofi Pasteur.Rosana Richtmann has received for lectures fees sponsored by Abbvie, Pfizer and MSD. Financial competing interest: none.Selma Merenlender is presently supported by SRRJ.Val\u00e9ria Valim has no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"17"}}